XML 237 R50.htm IDEA: XBRL DOCUMENT

Operating Segments (Tables)

6 Months Ended

12 Months Ended

Jun. 30, 2024

Dec. 31, 2023

Operating Segments [Abstract]

Schedule of Operating Segments

The Group’s CODM is the CEO of the Company.

		Six months ended June 30, 2024
		Drug Development				Online Sales				Total
Revenues
External		$	-			$	840			$	840
Total			-				840				840

Segment loss (gain)			3,040				487				3,527
Company’s share of losses of company accounted for at equity, net											208
Loss on impairment of intangible asset											-
Finance expense (income), net											(51	)
Tax expense (income)											(5	)

Loss											3,679

		Six months ended June 30, 2023
		Drug Development				Online Sales				Total
Revenues
External		$	-			$	1,972			$	1,972
Total			-				1,972				1,972

Segment loss (gain)			2,772				195				2,967
Company’s share of losses of company accounted for at equity, net											99
Loss on impairment of intangible asset											-
Finance expense (income), net											(147	)
Tax expense											13

Loss											2,932

		Year ended December 31, 2023
		Drug Development				Online Sales				Total
Revenues
External		$	-			$	2,879			$	2,879
Total			-				2,879				2,879

Segment loss (gain)			5,359				414				5,773
Company’s share of losses of company accounted for at equity, net											210
Loss on impairment of intangible asset											1,042
Finance expense (income), net											(1,164	)
Tax expense											22

Loss											5,883

		As of June 30, 2024
		Drug Development				Online Sales				Total

Segment Assets		$	6,834			$	3,648			$	10,482
Segment Liabilities		$	1,742			$	84			$	1,826

		As of June 30, 2023
		Drug Development				Online Sales				Total

Segment Assets		$	4,290			$	5,602			$	9,892
Segment Liabilities		$	2,741			$	373			$	3,114

		As of December 31, 2023
		Drug Development				Online Sales				Total

Segment Assets		$	7,069			$	4,113			$	11,182
Segment Liabilities		$	1,441			$	154			$	1,595

The Group’s CODM is the CEO of the Company.

		Year ended December 31, 2023
		Drug Development				Online Sales				Total
Revenues
External		$	-			$	2,879			$	2,879
Total			-				2,879				2,879

Segment loss (gain)			5,359				414				5,773
Company’s share of losses of company accounted for at equity, net											210
Loss on impairment of intangible asset											1,042
Finance expense (income), net											(1,164	)
Tax expense											22

Loss											5,883

		Year ended December 31, 2022
		Drug Development				Online Sales				Total
Revenues
External		$	-			$	1,347			$	1,347
Total			-				1,347				1,347

Segment loss			8,405				(118	)			8,287
Company’s share of losses of company accounted for at equity, net											109
Finance expense (income), net											(5,818	)
Tax expense											14

Loss											2,592

		Year ended December 31, 2021
		Drug Development				Online Sales				Total
Revenues
External		$	-			$	-			$	-
Total			-				-				-

Segment loss			5,768				-				5,768
Finance expense (income), net											21

Loss											5,789

		As of December 31, 2023
		Drug Development				Online Sales				Total

Segment Assets		$	7,069			$	4,113			$	11,182
Segment Liabilities		$	1,441			$	154			$	1,595

		As of December 31, 2022
		Drug Development				Online Sales				Total

Segment Assets		$	9,664			$	941			$	10,605
Segment Liabilities		$	4,021			$	135			$	4,156